Genmab A/S

GMAB · OMX

$43.79+$3.79 (+9.47%)TodayMarket closed · Oct 23, 7:57 PM ET

Prev close $40.00

GMAB analyst rating

BuyConsensus of 8 analysts over the last 12 months. 88% rate it a buy.

Strong buy0
Buy7
Hold1
Underperform0
Sell0

12-month price target · 21 analysts

Average $42.25 (−3.5% downside)

Low: $21.36
Now: $43.79
High: $63.43

Upgrades and downgrades

The latest rating actions, newest first

GMAB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 7, 2026	Maintains	Buy	$40.00 → $45.00	44%
Guggenheim	Oct 7, 2026	Maintains	Buy	$54.00 → $58.00	62%
HC Wainwright & Co.	Oct 7, 2026	Maintains	Buy	$40.00 → $50.00	43%
Guggenheim	Oct 5, 2026	Maintains	Buy	$45.00 → $54.00	62%
HC Wainwright & Co.	Sep 14, 2026	Maintains	Buy	$40.00	43%
Guggenheim	Aug 7, 2026	Maintains	Buy	$40.00 → $42.00	62%
TD Cowen	Jul 22, 2026	Upgrade	Hold → Buy	$32.00 → $43.00	49%
HC Wainwright & Co.	Jul 2, 2026	Maintains	Buy	$38.00 → $40.00	43%
HC Wainwright & Co.	Jun 23, 2026	Maintains	Buy	$38.00	43%
HC Wainwright & Co.	Apr 30, 2026	Maintains	Buy	$40.00 → $38.00	43%

The case for and against

Updated Oct 21, 2026

Bull case

Genmab is viewed favorably because its marketed portfolio combines durable revenue engines and multiple shots on goal, led by Darzalex in multiple myeloma and supported by Tepezza, Kesimpta, Rybrevant, Tivdak, and Epkinly across large oncology and autoimmune markets. The positive Phase 3 EPCORE DLBCL-2 readout, with EPKINLY + R-CHOP reducing progression or death risk by 51% (PFS HR 0.49), materially de-risks a first-line DLBCL expansion and increases confidence in meaningful commercial uptake. Beyond that, Rinatabart sesutecan’s 45.9% confirmed ORR in 109 heavily pretreated ovarian cancer patients, with 9.5-month mPFS and low discontinuation, strengthens the pipeline and supports further upside from underappreciated late-stage assets.

Bear case

Genmab is viewed negatively because its valuation depends heavily on assumptions that can quickly weaken if key products underperform, while the business still faces R&D, regulatory, legal, commercial, and competitive setbacks. The investment case is especially exposed to slowing DARZALEX sales, possible negative EPKINLY trial readouts, and lower-than-expected penetration across newer therapies, any of which could pressure revenue durability. On top of that, financing risks tied to the Merus acquisition and associated debt, plus acquisition and integration charges of 43.5, 185.0, 45.0, 32.0, and 77.0, add dilution and earnings uncertainty.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.